Bevacizumab Biosimilar - Research Grade
Product Specifications
Background
Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium.
Product Name Alternative
Vascular endothelial growth factor
UniProt
P15692
Host
Humanized
Reactivity
Human
Target
VEGF
Isotype
IgG1
Sequence
https://www.imgt.org/mAb-DB/
Purification Method
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Concentration
1.0 - 5.0 mg/mL
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>95% by SDS-PAGE and HPLC
Buffer
ICH3001-100ml ICH3002-100ml ICH3003-100ml
Shipping Conditions
Blue ice
Storage Conditions
Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Specificity
Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab.
Formulation
Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free.
Isotype Control
Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
038734-AP 200 µL
MYL3, NT (MYL3, Myosin light chain 3, Cardiac myosin light chain 1, Myosin light chain 1, slow-twitch muscle B/ventricular isoform, Ventricular/slow twitch myosin alkali light chain) (AP) discontinued
Ask
View Details 
